Mark G. Kris

Mark G. Kris

Auto-generated profile, based on publicly available information

Mark G. Kris

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WPWilliam Pao
William Pao
VMVincent Miller
Vincent Miller
MZMaureen Zakowski
Maureen Zakowski
JDJennifer Doherty
Jennifer Doherty
KPKaterina Politi
Katerina Politi
HVHarold Varmus
Harold Varmus
Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors ( P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors ( P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (“never smokers”), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers ( P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.

22 February 2005 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
WPWilliam Pao
William Pao
VMVincent A Miller
Vincent A Miller
KPKaterina A Politi
Katerina A Politi
GRGregory J Riely
Gregory J Riely
RSRomel Somwar
Romel Somwar
HVHarold Varmus
Harold Varmus
Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial responses, patients eventually progress by unknown mechanisms of “acquired” resistance. We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain. Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation. This mutation was not detected in untreated tumor samples. Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs. Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib. Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec). In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug. This observation should help guide the search for more effective therapy against a specific subset of lung cancers.

15 April 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HYHelena A. Yu
Helena A. Yu
MAMaria E. Arcila
Maria E. Arcila
NRNatasha Rekhtman
Natasha Rekhtman
CSCamelia S. Sima
Camelia S. Sima
MZMaureen F. Zakowski
Maureen F. Zakowski
GRGregory J. Riely
Gregory J. Riely
Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish the frequency of various mechanisms has not been conducted. Experimental Design: Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance. Histology was reviewed. Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2. Results: Adequate tumor samples for molecular analysis were obtained in 155 patients. Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%–70%] and four had small cell transformation (3%, 95% CI, 0%–6%). MET amplification was seen in 4 of 75 (5%; 95% CI, 1%–13%). HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%–32%). We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%–4%). Overlap among mechanisms of acquired resistance was seen in 4%. Conclusions: This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy. We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histologic transformation occur less frequently. More comprehensive methods to characterize molecular alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs. Clin Cancer Res; 19(8); 2240–7. ©2013 AACR.

22 October 2003 in JAMA
Verified
Journal Article
Open access
PDF file
MKMark G. Kris
Mark G. Kris
RNRonald B. Natale
Ronald B. Natale
RHRoy S. Herbst
Roy S. Herbst
JLJr Thomas J. Lynch
Jr Thomas J. Lynch
DPDiane Prager
Diane Prager
AKAndrea C. Kay
Andrea C. Kay
More persons in the United States die from non–small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined.1 Each year, more than 60 000 persons develop stages IIIB and IV NSCLC; nearly all go on to die from metastatic spread. In addition, most individuals experience symptoms caused directly by lung cancer. These symptoms are often the first manifestations of the illness and increase in frequency and severity as the disease progresses. Cough, shortness of breath, weight loss, loss of appetite, and chest tightness impair the quality of lives already cut short by NSCLC. For patients with advanced lung cancer, physical well-being and changes in quality of life correlate with survival.2 Especially among patients with metastatic NSCLC, who are rarely cured, lessening lung cancer symptoms without adding burdensome adverse effects is an important goal of care. No anticancer therapy has been proven to be beneficial to persons seeking additional care after receiving 2 or more chemotherapy regimens.

21 May 2014 in JAMA
Verified
Journal Article
Open access
PDF file
MKMark G. Kris
Mark G. Kris
BJBruce E. Johnson
Bruce E. Johnson
LBLynne D. Berry
Lynne D. Berry
DKDavid J. Kwiatkowski
David J. Kwiatkowski
AIA. John Iafrate
A. John Iafrate
PBPaul A. Bunn
Paul A. Bunn
Quiz Ref ID The introduction of targeted therapy has transformed the care of patients with lung cancers by incorporating tumor genotyping into therapeutic decision making. Adenocarcinoma, the most common type of lung cancer, is diagnosed in 130 000 patients in the United States and 1 million persons worldwide each year.1 It is also the type of lung cancer with a higher than 50% estimated frequency of actionable oncogenic drivers.2,3 The Lung Cancer Mutation Consortium (LCMC) collectively termed these molecular abnormalities oncogenic drivers to include multiple types of genomic changes and emphasize that unlike many biomarkers and “passenger” mutations, these alterations are critical to cancer development and maintenance. The LCMC further defined these drivers as actionable based on the demonstration that the downstream effects of these abnormalities that initiate or maintain the neoplastic process can be negated by agents directed against each genomic alteration. Testing for somatic mutations in the epidermal growth factor receptor (EGFR) gene4-6 and rearrangements of the anaplastic lymphoma kinase (ALK) gene7 is now routine.8

25 January 2005 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
WPWilliam Pao
William Pao
TWTheresa Y Wang
Theresa Y Wang
GRGregory J Riely
Gregory J Riely
VMVincent A Miller
Vincent A Miller
QPQiulu Pan
Qiulu Pan
HVHarold E Varmus
Harold E Varmus
Somatic mutations in the gene for the epidermal growth factor receptor (EGFR) are found in adenocarcinomas of the lung and are associated with sensitivity to the kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive. We sought to determine whether mutations in KRAS could be used to further enhance prediction of response to gefitinib or erlotinib. We screened 60 lung adenocarcinomas defined as sensitive or refractory to gefitinib or erlotinib for mutations in EGFR and KRAS. We show that mutations in KRAS are associated with a lack of sensitivity to either drug. Our results suggest that treatment decisions regarding use of these kinase inhibitors might be improved by determining the mutational status of both EGFR and KRAS.